about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsPim-1 kinase as cancer drug target: An updateThe role of PIM1/PIM2 kinases in tumors of the male reproductive systemTargeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subsetAntiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cellsIdentification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.Exploring the key genes and pathways in enchondromas using a gene expression microarray.β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition.A functional SUMO-motif in the active site of PIM1 promotes its degradation via RNF4, and stimulates protein kinase activity.PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells.Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Thyroid hormone inhibits growth of hepatoma cells through induction of miR-214.mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.Gelsolin regulates proliferation, apoptosis and invasion in NK/T-cell lymphoma cells.Hijacking of the AP-1 Signaling Pathway during Development of ATL.Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
P2860
Q26752940-909D9AAD-5D3C-4804-8418-C0F324AB322CQ26766319-767694EC-966B-4B13-929C-EF45E543803CQ28273475-3E651DBA-8831-488F-9ECE-68BA77D57CC7Q28818309-61180071-C483-427C-924B-1D59607917BCQ33728277-D44A2E77-A366-49C4-94E7-324A107F33BEQ33889083-E3963BB5-8AF0-4B84-BE3D-5B7334B070A8Q35627487-C4C15627-F262-408A-A963-9D1317245FDEQ36080785-4B895177-F344-4782-B1B1-EA7F76C00A2BQ36276942-9A66F83A-A30A-47E9-938E-9557A00684ABQ37536530-51446359-DFBE-41BD-89B0-487D031389D6Q37569554-52C3E852-4E4E-4D71-AF0B-75D2F58943CCQ38261268-E5352ADF-65AE-41A7-9B40-AF5B22F0DD0CQ38434804-C977757F-7466-443E-A684-4DD8729BCCB6Q38710607-6C51AE75-E104-4670-B0A6-7769D529355AQ38723222-036FBDC3-9727-45BA-A60C-06ABB9255DE6Q38769889-370E4285-592C-45D9-B09A-15ED7E68F32BQ38792750-400CB01B-085A-4AC9-8F63-AF9E379D7D8FQ38960311-8EBA208B-924D-4DC9-A64B-25E6F1C6E38CQ40066265-F6C208FD-4FED-4337-A23A-6547204154FEQ40591054-1BAE0A53-5C39-4F55-9708-0F8642B5B8D6Q41035643-E4F48779-5B93-4FC4-B205-8F5EC275603DQ41190385-01153BB6-C854-45E5-B40E-9AE768FB155FQ41708939-76B981E0-E290-46F3-B965-563320ED2B90Q42130801-AF5368ED-C48A-40FC-949E-DA2C72AFA78CQ42319925-E7580BEC-A1FF-4349-ADF6-F17DBFA0EBE4Q46973951-7EFA0E8C-F2D0-4C62-800F-1124D7B62235Q47352692-366DD4FB-5B6A-48A1-AA71-76C5BB089816Q47364413-4502675E-1076-4A7D-A980-1790230D089FQ47548071-BFF986FD-F6C9-418F-8D75-E9C54C9FD3CDQ47554666-4DBC43D6-28B9-41F8-8FFD-6C7EA5333677Q52344482-D44FB86C-376D-4371-A54A-2F0AEFE488FEQ52366350-852D66BD-23D6-4948-8CD8-DA76917014FBQ52582842-9BA2E3FB-AFEF-403B-BF0D-A4FC099FA68BQ54978680-B6825E9C-57F3-4153-AD4F-CEA86C1DB00FQ54984581-EE894B63-CD00-43A6-86F3-38662235EE6D
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PIM kinase (and Akt) biology and signaling in tumors.
@en
type
label
PIM kinase (and Akt) biology and signaling in tumors.
@en
prefLabel
PIM kinase (and Akt) biology and signaling in tumors.
@en
P2860
P1476
PIM kinase (and Akt) biology and signaling in tumors
@en
P2093
Andrew S Kraft
P2860
P356
10.1016/J.PHARMTHERA.2015.03.001
P577
2015-03-05T00:00:00Z